Program
darolutamide
Also written as “Darolutamide”, “Darolutamide (Nubeqa, BAY1841788)” and “Darolutamide (BAY1841788, Nubeqa)”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Bulbo-Spinal Atrophy, X-Linked · Neoplasms · Neoplasm Metastasis, led by 2 companies.
Drug pageDarolutamide: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 164 open or running | phase 4since Apr 21, 2022 | Jul 22, 2014 | Jul 30, 2027phase 3 · NCT05794906 |
| Orion Corporation, Orion Pharmaits history only | 40 open or running | phase 2since Mar 7, 2011 | Mar 7, 2011 | none ahead |
Also a collaborator on its studies: Keenova Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Mar 7, 2011.
- Jun 6, 2016Phase 3 study in Metastatic Hormone-sensitive Prostate CancerBayer · NCT02799602 · 1,306 enrolled · United States, Australia, Belgium and more
- Jun 9, 2016Named darolutamideINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ODM-201
- Aug 29, 2016Phase 1 study in Hepatic InsufficiencyBayer · NCT02894385 · 29 enrolled · Germany
- Feb 8, 2017Phase 1 study in Biological AvailabilityBayer · NCT03048110 · 15 enrolled · Germany
- Jul 26, 2017Phase 1 study in Prostatic NeoplasmsBayer · NCT03237416 · 15 enrolled · Germany
- Oct 10, 2018Phase 1 study in Cerebrovascular CirculationBayer · NCT03704519 · 26 enrolled · United Kingdom
- Oct 21, 2019Phase 2 study in Prostatic Neoplasms, Castration-ResistantBayer · NCT04157088 · 30 enrolled · United States
- Jul 7, 2020Phase 3 study in NeoplasmsBayer · NCT04464226 · 774 enrolled · United States, Argentina, Australia and more
- Jan 29, 2021Phase 3 study in Prostatic NeoplasmsBayer · NCT04736199 · 669 enrolled · Australia, Brazil, Canada and more
- Sep 17, 2021Phase 2 study in Prostatic NeoplasmsBayer · NCT05059236 · 223 enrolled · United States
- Apr 21, 2022Phase 4 study in Prostatic NeoplasmsBayer · NCT05348876 · 50 planned · India
- Aug 31, 2022Phase 2 study in Biochemically Recurrent Prostate CancerBayer · NCT05526248 · 28 enrolled · United States
- Mar 21, 2023Phase 3 study in Biochemically Recurrent Prostate CancerBayer · NCT05794906 · 985 enrolled · United States, Australia, Austria and more
- Feb 12, 2026Phase 2 study in High-risk Localized Prostate CancerBayer · NCT07450599 · 250 planned · China
- Nov 5, 2026Primary completion moved from 2027-04-29 to 2027-12-30Date moved laterphase 4 · +8 months · NCT05348876
Ahead
- Jul 30, 2027Primary completion: phase 3 study in Biochemically Recurrent Prostate CancerBayer · NCT05794906
- Dec 30, 2027Primary completion: phase 4 study in Prostatic NeoplasmsBayer · NCT05348876
- Jun 26, 2028Primary completion: phase 3 study in NeoplasmsBayer · NCT04464226
- Oct 15, 2028Primary completion: phase 2 study in High-risk Localized Prostate CancerBayer · NCT07450599
TargetBeta
“A formulation containing an androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07450599High-risk Localized Prostate Cancer · China | 2 | Recruiting | Bayer | Oct 15, 2028 | 250 |
| NCT05794906Biochemically Recurrent Prostate Cancer · United States, Australia, Austria and more | 3 | Active, not recruiting | Bayer | Jul 30, 2027 | 985 |
| NCT05526248Biochemically Recurrent Prostate Cancer · United States | 2 | Completed | Bayer | Aug 20, 2024 | 28 |
| NCT05348876Prostatic Neoplasms · India | 4 | Recruiting | Bayer | Dec 30, 2027 | 50 |
| NCT05059236Prostatic Neoplasms · United States | 2 | Completed | Bayer | May 30, 2025 | 223 |
| NCT04736199Prostatic Neoplasms · Australia, Brazil, Canada and more | 3 | Completed | Bayer | Jun 7, 2024 | 669 |
| NCT04464226Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bayer | Jun 26, 2028 | 774 |
| NCT04157088Prostatic Neoplasms, Castration-Resistant · United States | 2 | Terminated | Bayer | Jul 8, 2022 | 30 |
| NCT03704519Cerebrovascular Circulation · United Kingdom | 1 | Completed | Bayer | Oct 1, 2019 | 26 |
| NCT03237416Prostatic Neoplasms · Germany | 1 | Completed | Bayer | Oct 5, 2017 | 15 |
| NCT03048110Biological Availability · Germany | 1 | Completed | Bayer | May 4, 2017 | 15 |
| NCT02894385Hepatic Insufficiency · Germany | 1 | Completed | Bayer | Apr 10, 2017 | 29 |
| NCT02799602Metastatic Hormone-sensitive Prostate Cancer · United States, Australia, Belgium and more | 3 | Completed | Bayer | Oct 25, 2021 | 1,306 |
| NCT02671097Healthy Volunteers · Germany | 1 | Completed | Bayer | May 2016 | 30 |
| NCT02418650Healthy · United Kingdom | 1 | Completed | Orion Corporation, Orion Pharma | May 2015 | 12 |
| NCT02363855Prostatic Neoplasms · Japan | 1 | Completed | Bayer | Nov 19, 2015 | 9 |
| NCT02200614Prostate Cancer Non-Metastatic · United States, Argentina, Australia and more | 3 | Completed | Bayer | Sep 3, 2018 | 1,509 |
| NCT01784757Prostatic Neoplasms · Latvia | 1 | Completed | Orion Corporation, Orion Pharma | Aug 2013 | 30 |
| NCT01429064Prostatic Neoplasms · United States, Czech Republic, Estonia and more | 2 | Completed | Orion Corporation, Orion Pharma | Nov 2015 | 76 |
| NCT01317641Prostatic Neoplasms · United States, Czech Republic, Estonia and more | 2 | Completed | Orion Corporation, Orion Pharma | Jul 2013 | 136 |
How it is read
Names in the registry
- “Darolutamide”, 6 entries
- “Darolutamide (Nubeqa, BAY1841788)”, 5 entries
- “Darolutamide (BAY1841788, Nubeqa)”, 2 entries
- “BAY1841788 (ODM-201)”, 2 entries
- “ODM-201”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 15 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.